Search results
Showing 1861 to 1875 of 2042 results for guidelines
NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions
NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .
NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the fast track appraisal.
NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
Otovent nasal balloon for otitis media with effusion (MIB59)
NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.